Carbetocin Evidence Guide
Carbetocin (Duratocin) is approved in Canada, Europe, and other markets for postpartum hemorrhage prevention following cesarean delivery, with Phase 3 data from the WHO CHAMPION trial confirming non-inferiority to oxytocin. It is not FDA-approved in the US. Its longer duration of action (4-7 hours vs. minutes for oxytocin) is its clinical differentiator. A legitimate approved drug in its specific obstetric niche.
Our Take
Carbetocin (Duratocin) is approved in Canada, Europe, and other markets for postpartum hemorrhage prevention following cesarean delivery, with Phase 3 data from the WHO CHAMPION trial confirming non-inferiority to oxytocin. It is not FDA-approved in the US. Its longer duration of action (4-7 hours vs. minutes for oxytocin) is its clinical differentiator. A legitimate approved drug in its specific obstetric niche.
- Best for
- Postpartum hemorrhage prevention (cesarean delivery), long-acting oxytocin receptor agonist research
- Evidence grade
- Level B
- Confidence
- Moderate
- Starting point
- 100mcg IV single dose immediately after delivery
Benefits and Evidence
- Postpartum Hemorrhage Prevention: Level A, includes human evidence - The WHO CHAMPION trial (nearly 30,000 women) demonstrated that heat-stable carbetocin was non-inferior to oxytocin for PPH prevention. Multiple RCTs confirm efficacy after both cesarean and vaginal delivery.
- Reduced Need for Additional Uterotonics: Level B, includes human evidence - Single-dose carbetocin reduces the need for supplementary uterotonic agents compared to oxytocin infusion, simplifying postpartum management.
- Uterine Tone Maintenance: Level B, includes human evidence - Duration of uterotonic effect (60-120 minutes) exceeds that of a single oxytocin dose (15-30 minutes), providing more sustained uterine tone.
Side Effects and Warnings
- Abdominal pain
- Nausea
- Flushing
- Headache
- Tremor
- Hypotension
- Pruritus
- Metallic taste
Research Dosage References
- <strong>Intravenous</strong> - 100 mcg - Single dose after delivery - Administered as slow IV bolus over 1 minute immediately after delivery of the baby (cesarean) or placenta (vaginal). No repeat dosing required.
- <strong>Intramuscular</strong> - 100 mcg - Single dose after delivery - IM route used in settings where IV access is limited. Heat-stable formulation does not require refrigeration.
Mechanism of Action
Carbetocin acts as a long-acting oxytocin receptor agonist: 1. Oxytocin receptor binding: Binds to the oxytocin receptor (OXTR) on myometrial smooth muscle cells with affinity comparable to oxytocin. 2. Sustained uterine contraction: Induces prolonged rhythmic uterine contractions through calcium mobilization via phospholipase C/IP3 signaling. Single dose provides uterotonic effect lasting 60-120 minutes. 3. Enzymatic resistance: Modified structure resists degradation by aminopeptidases and disulfidases that rapidly inactivate native oxytocin. 4. Hemostatic compression: Sustained uterine contraction compresses blood vessels at the placental site, preventing excessive postpartum blood loss.
Legal Status
Approved in over 30 countries including EU and Canada (Duratocin/Pabal). FDA-approved. On the WHO List of Essential Medicines (heat-stable formulation). Prescription only.
Primary Sources
- Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth (CHAMPION trial). New England Journal of Medicine, 2018.
- Carbetocin versus oxytocin for prevention of postpartum hemorrhage at cesarean section. BJOG, 2010.
- Carbetocin for preventing postpartum hemorrhage: a systematic review. Obstetrical & Gynecological Survey, 2012.